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L-arginine promotes gut hormone release and reduces food
intake in rodents
A. Alamshah1, A. K. McGavigan1, E. Spreckley1, J. S. Kinsey-Jones1, A. Amin1, I. R. Tough2, H. C. O’Hara1,
A. Moolla1, K. Banks1, R. France1, G. Hyberg3, M. Norton1, W. Cheong1, A. Lehmann3,4, S. R. Bloom1,
H. M. Cox2 & K. G. Murphy1
1Section of Endocrinology and Investigative Medicine, Department of Medicine, Imperial College London, London, UK
2Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
3AstraZeneca R&D, Mölndal, Sweden
4Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Aims: To investigate the anorectic effect of L-arginine (L-Arg) in rodents.
Methods: We investigated the effects of L-Arg on food intake, and the role of the anorectic gut hormones glucagon-like peptide-1 (GLP-1) and peptide
YY (PYY), the G-protein-coupled receptor family C group 6 member A (GPRC6A) and the vagus nerve in mediating these effects in rodents.
Results: Oral gavage of L-Arg reduced food intake in rodents, and chronically reduced cumulative food intake in diet-induced obese mice. Lack of the
GPRC6A in mice and subdiaphragmatic vagal deafferentation in rats did not influence these anorectic effects. L-Arg stimulated GLP-1 and PYY release
in vitro and in vivo. Pharmacological blockade of GLP-1 and PYY receptors did not influence the anorectic effect of L-Arg. L-Arg-mediated PYY release
modulated net ion transport across the gut mucosa. Intracerebroventricular (i.c.v.) and intraperitoneal (i.p.) administration of L-Arg suppressed food
intake in rats.
Conclusions: L-Arg reduced food intake and stimulated gut hormone release in rodents. The anorectic effect of L-Arg is unlikely to be mediated by
GLP-1 and PYY, does not require GPRC6A signalling and is not mediated via the vagus. I.c.v. and i.p. administration of L-Arg suppressed food intake in rats,
suggesting that L-Arg may act on the brain to influence food intake. Further work is required to determine the mechanisms by which L-Arg suppresses
food intake and its utility in the treatment of obesity.
Keywords: animal pharmacology, body composition, energy regulation, GLP-1, obesity therapy
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Introduction
High protein diets promote satiety andweight loss [1,2], but the
exact mechanismsmediating these effects are unclear. Evidence
suggests, however, that protein is sensed within the gastroin-
testinal tract, modulating appetite-regulating pathways [3].
Mechanisms proposed to mediate the effects of high pro-
tein diets on food intake, include increased thermogenesis,
intestinal gluconeogenesis and changes in gut hormone profiles
[4]. Such mechanisms may be instigated by the sensing of the
amino acids produced by protein digestion. Rodents adapt their
diet to balance amino acid intake [5]. Different types of protein
can result in different levels of satiety [6], perhaps reflecting
their different amino acid compositions. The recent discovery
of promiscuous L-amino acid-sensing G-protein-coupled
receptors and their expression in the gastrointestinal tract has
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driven speculation that these receptors are involved in amino
acid sensing and the regulation of food intake. These receptors
include the calcium-sensing receptor (CaSR), the T1R1-T1R3
umami taste receptor complex and the G-protein-coupled
receptor family C group 6 member A (GPRC6A) [7].
Amino acids may be sensed in the gut to promote the
release of anorectic gut hormones [8]. The aromatic amino
acids L-phenylalanine and L-tryptophan induce the release of
cholecystokinin (CCK) from isolated I-cells [9]. The anorec-
tic gut hormones glucagon-like peptide-1 (GLP-1) and peptide
YY (PYY) (3-36) are released from enteroendocrine L-cells in
response to nutrients, including amino acids [10]. Ingestion of
a high protein meal alters circulating GLP-1 and PYY levels
and promotes their release in both humans and rodents [11,12].
These hormones may act directly on appetite-regulating areas
of the brain, but may also have indirect effects. The vagus
nerve is one of the major extrinsic nerves, with a key role
in the gut–brain axis. Evidence suggests that vagal signalling
is involved in the regulation of food intake, and may play
a role in gut hormone-mediated satiety. Vagal afferents relay
mechanosensory and chemosensory signals from the gut to
the nucleus of the solitary tract within the brainstem. In addi-
tion, specific gut hormones, in particular CCK, but also ghrelin,
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PYY(3-36) and GLP-1, have been reported to exert their effects
on appetite and food intake via vagal afferents [13].
The ability of specific L-amino acids, including L-arginine
(L-Arg), to stimulate GLP-1 and PYY release has been stud-
ied previously in vitro [14,15]. L-Arg, a conditionally essential
amino acid, is derived from the diet, endogenous synthesis and
protein turnover [16]. L-Arg has a well-characterized effect as a
secretagogue promoting insulin release from pancreatic 𝛽-cells
[17]. Oral L-Arg can also stimulate insulin secretion by promot-
ing GLP-1 release, improving glucose tolerance in mice [18].
L-Arg is a potent agonist of GPRC6A [19], and it has been
suggested that GPRC6A activity is necessary for some effects
of L-Arg on glucose homeostasis [20]. Furthermore, GPRC6A
was required for ornithine-induced GLP-1 release from an in
vitro model [21], suggesting that GPRC6A may play a role in
L-Arg-mediated hormone release. In addition, L-Arg can stim-
ulate growth hormone release from the pituitary, although the
mechanism is unclear [22].
L-Arg thus has established effects on hormone release and
metabolism. Recent evidence suggests that L-Arg may also
be involved in the regulation of food intake [23]; therefore,
we investigated the effect of L-Arg on gut hormone release
and energy homeostasis in rodents, and explored the potential
mechanisms mediating its effects on gut function and food
intake.
Materials and Methods
Animals
Male C57BL/6 mice, 8–10weeks (Harlan, Bicester, UK)
and male Wistar rats (200–250 g) (Charles River, Margate,
UK) were individually housed under controlled temperature
(21–23 ∘C) and humidity on a 12 h light : 12 h darkness cycle.
All the animals had ad libitum access to standard chow RM1
(SDS, Witham, UK) and water, and were randomized by body
weight, unless stated otherwise. The GPRC6A knock-out
(GPRC6a-KO) model used in the present studies was gener-
ated by the trans-NIH Knock-Out Mouse Project (KOMP)
and obtained from the KOMP Repository. The deleted region
completely covers the GPRC6a locus [24], and thus this model
differs from others previously described [25,26]. The glucose
homeostasis phenotype of the knock-out model was assessed
before performing feeding studies to address the conflicting
reported phenotypes of other GPRC6a KO models [25,27]. All
animal procedures were approved and performed under the
UK Home Office Animals (Scientific Procedures) Act 1986.
Feeding Studies
Animals were randomized by body weight and acclimatized to
the procedures before all studies. Because of the basic nature
of L-Arg solution, L-Arg monohydrochloride (L-Arg·HCl)
neutral salt was used in all experiments. For the fasted studies,
animals were fasted for 16 h overnight before receiving water
or L-Arg·HCl (Sigma, Poole, UK), at doses stated (Table S1,
File S1), in the early light phase by either oral gavage (o.g.)
or intraperitoneal (i.p.) injection. For ad libitum-fed animal
studies, the same administration procedure was used without
fasting in either the early light phase or at the onset dark
phase. For the study investigating the role of gut hormones
in mediating the effect of L-Arg on food intake, fasted or ad
libitum-fedmice were given simultaneous i.p. administration of
400 nmol/kg exendin 9-39 (GLP-1R antagonist) and BIIE0246
(Y2 receptor antagonist) at 5.26 μmol/kg 15min before the o.g.
administration of water or 24mmol/kg L-Arg. Animals were
returned to their cages, with pre-weighed amounts of standard
chow diet and food intake measured 1, 2, 4, 8 and 24 h after
administration. The GPRC6a-KO mice feeding studies used
a crossover design, in which GPRC6a-KO and wild-type (wt)
mice received both control and L-Arg treatments in random
order on separate occasions separated by at least 3 days; accord-
ingly, food intake was compared and analysed using a paired
analysis approach. A summary of all feeding studies, including
doses, species and time of day of the study, is provided in
Table S1, File S1.
Energy Expenditure Studies
Mice were individually housed in a 24-chamber open-circuit
comprehensive laboratory animalmonitoring system (CLAMS;
Columbus Instruments, OH, USA) and acclimatized for 24 h
to generate stable reference data. They were then fasted for
16 h overnight and subsequently received water or 24mmol/kg
L-Arg o.g. (n= 12/group) at 09:00 hours (early light phase).
The mice continued to be fasted for the subsequent 8 h, to
examine the effects of L-Arg on energy expenditure, indepen-
dent of effects on food intake, before food was returned at
17:00 hours. Metabolic variables (VO2 and VCO2) and the res-
piratory exchange ratio (RER) were measured every 24min for
24 h after treatment administration, and values normalized to
body weight [28].
Chronic Feeding Studies in Mice
Male mice, aged 6–8weeks, were group-housed (five per cage)
with ad libitum access to water and a 60% high fat diet
(Research Diets, New Brunswick, NJ, USA) for 8weeks. The
mice were then individually housed and given 1week to accli-
matize before the study started, remaining on the high fat diet.
Mice were given water or 16mmol/kg L-Arg o.g. (n= 9 per
group) twice daily throughout the dark phase at 19:00 hours and
then 01:00 hours for five nights. Body weight and food intake
were measured daily at the beginning of the dark phase and at
1 h after the first daily gavage.
Subdiaphragmatic Vagal Deafferentation Surgery in Rats
Subdiaphragmatic vagal deafferentation (SDA) was carried out
in rats, as previously described [29,30], as it results in more
accurate deafferentation and lower morbidity than inmice.The
effect of oral administration of water or 16mmol/kg L-Arg
(n= 9–10, crossover) on food intake was then studied in
overnight fasted rats during the early light phase.
Murine Colonic Crypt Isolation and Hormone Secretion
Assays
Primary mice colonic crypt isolation and secretion studies
were performed using an adaptation of an established method
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previously described [31,32]. Gut hormone secretion was
expressed as a fraction of the total peptide (secreted plus
intracellular) measured in each well over 2 h.
In Vitro Mucosal Studies
Ileal or colonic mucosa from wt male mice (>15weeks old),
was voltage-clamped at 0mV in Ussing chambers, as described
previously [33]. Vectorial ion transport was measured contin-
uously as short-circuit current (Isc; 𝜇A/cm2) and provided an
acute readout for endogenous PYY release. Once stable Isc lev-
els were achieved, vehicle or the Y1 receptor (Y1R) antagonist
BIBO3304 (BIBO; 300 nM) and L- or D-Arg were added to the
apical or basolateral reservoirs bathingmucosae. L-Arg (1mM)
responses were measured 15–20min after vasoactive intestinal
peptide (10 nM), an optimum secretory stimulus for revealing
subsequent G𝛼i-coupled epithelial responses [33]. Epithelial Y
agonism results from G𝛼i-coupled attenuation of cAMP levels,
with consequent sustained decreases in Cl− ion secretion and
Isc levels [34], thus PYY (10 nM) was added after L-Arg as a
control.
In Vivo Gut Hormone Studies
Rats were fasted overnight, before receiving o.g. of either water
or 16mmol/kg L-Arg (n= 6–8) in the early light phase. They
were immediately returned to their cages, killed by decapitation
at 30 or 90min after administration, and plasma samples were
collected as previously described [29].
Intra-ileal Administration Studies
Intra-ileal administration procedures were performed in anaes-
thetized rodents as previously described [32]. Rats received an
injection of either saline or 1M L-Arg (n= 4–5) in a volume
of 2.5ml into the upper ileum; blood samples were collected
at −15, 0, 15, 30, 45 and 60min post-administration via the
jugular cannula. Mice were injected with either saline or 1M
L-Arg (n= 4–5) in a volume of 500 μl into the upper ileum,
and were killed 30min after administration and blood was
collected.
Gut Hormone Radioimmunoassay
We measured GLP-1 and PYY using previously established
in-house specific and sensitive radioimmunoassays [35,36].
The GLP-1 antibody has 100% cross-reactivity with all ami-
dated forms of GLP-1, but does not cross-react with glycine
extended forms. The PYY antibody has 100% cross-reactivity
with PYY(1-36) and PYY(3-36). The intra-assay coefficients
of variation for GLP-1 and PYY assays were 8.7 and 6.0%,
respectively.
Intracerebroventricular Cannulation and Administration
The intracerebroventricular (i.c.v.) injections were carried out
as previously described [37]. The rats recovered from surgery
for 7 days before being injected with 5 μl of either vehicle saline
control or 4𝜇M L-Arg (n= 8–9) over 1min using a 28-gauge
stainless steel injector in the early light phase.
Statistical Analyses
Acute feeding studies data and area under the curve data are
expressed as mean± standard error of the mean (s.e.m.) and
were analysed using one-way analysis of variance (anova) fol-
lowed by Tukey’s post hoc test. CLAMS data were analysed
using two-way anova and a Bonferroni post hoc test, chronic
and SDA feeding study data using multiple Student’s t-test,
GPRC6a-KO feeding data using two-way anova with Sidak’s
post hoc analysis, and in vitro and in vivo gut hormone data
using one-way anovawith Dunnett’s and two-way anovawith
Bonferroni’s post hoc test, respectively. Mucosal data measuring
themaximum changes in Isc, are expressed asmean± s.e.m. per
unit area (cm2), and single comparisons performed using Stu-
dent’s unpaired t-test. Graphpad Prism software (Prism 6.03,
GraphPad Software Inc, CA, USA) was used for all analyses.
Results
Effect of Oral L-Arginine on Food Intake, Body Weight
and Energy Expenditure in Rodents
Oral administration of L-Arg significantly reduced food intake
in both rats and mice (Figure 1). In rats, oral administration
of L-Arg suppressed food intake in fasted rats in the early light
phase (Figure 1A) and in ad libitum-fed rats in the early dark
phase (Figure 1B). Similarly, oral administration of L-Arg in
fasted mice reduced food intake in a dose-dependent manner
(Figure 1C). Oral administration of L-Arg in ad libitum-fed
mice significantly reduced cumulative food intake 24 h after
administration in the light and dark phases (Figure 1D and
E). These anorectic effects were not secondary to abnormal
behavioural side effects in rats (Figure S1, File S1).
After observing that L-Arg administration could result in
a sustained reduction in food intake in rodents, we investi-
gated whether this anorectic effect could be sustained chron-
ically and reduce body weight in a diet-induced obese (DIO)
mouse model, a commonly used model of obesity. Repeated
L-Arg administration significantly reduced food intake on day
1 and day 2 in DIO mice compared with vehicle-treated mice
(Figure 1F), although this effect was insufficient to significantly
change body weight over the time period studied (Figure 1G).
To investigate the effect of L-Arg on energy expenditure, the
mice were placed in CLAMS metabolic cages. Oral adminis-
tration of 24mmol/kg L-Arg had no significant effect on VO2,
VCO2 or RER inmice during the 8 h after administration. Inter-
estingly, oral administration of 24mmol/kg L-Arg still reduced
food intake when food was returned 8 h after administration
in mice placed in CLAMS cages, showing a delayed and sus-
tained anorectic effect (Figure 1H). Returning food did not sig-
nificantly alter VO2 or VCO2 between the treatment groups
(Figure 1I and J); however, the RER was significantly lower in
L-Arg-treated mice, after the return of food (Figure 1K).
GPRC6A is Not Required for the Anorectic Effect
of L-Arginine in Mice
Oral administration of 16 or 24mmol/kg L-Arg significantly
reduced food intake in both wt and GPRC6a-KO mice to a
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Figure 1. Effect of oral administration of L-arginine (L-Arg) on food intake, body weight and energy expenditure in rodents. Effect of oral gavage (o.g.)
of control (water) and 8 and 16mmol/kg L-Arg on food intake in male rats (A) after an overnight fast [n= 9–10; ##P< 0.01 vs. L-Arg (8mmol/kg),
***P< 0.001 vs. water control] and (B) ad libitum fed at the beginning of dark phase (n= 12–16; *P< 0.05, **P< 0.01, ***P< 0.01 vs. water control, #P< 0.05
vs. 8mmol/kg L-Arg) at 0–1, 1–2, 2–4, 4–8 and 0–24 h after administration. (C) Effect of o.g. of control (water) and 8, 16 and 24mmol/kg L-Arg on food
intake inmalemice after an overnight fast at 0–1, 1–2, 2–4, 4–8 and 0–24 h after administration (n= 8–9; *P< 0.05, ***P< 0.001 vs. water control; #P< 0.05,
##P< 0.01 vs. 8mmol/kg L-Arg; $P< 0.05 vs. 16mmol/kg L-Arg). Effect of o.g. of control (water) or 24mmol/kg L-Arg in ad libitum-fed mice during the
early light phase (D) (n= 10 per group), and (E) early dark phase (n= 10 per group) at 0–1, 1–2, 2–4, 4–8, and 0–24 h after administration (*P< 0.05,
**P< 0.01 ***P< 0.001 vs. control). Effect of repeated o.g. administration of L-Arg on food intake (F) and body weight (G) in diet-induced obese (DIO)
mice. Effect of three times daily o.g. administration of control (water; black circles, solid line) or 16mmol/kg L-Arg (white circles, dotted line) on cumulative
food intake and body weight change in DIOmice during a period of 5 days (n= 9 per group; *P< 0.05, ***P< 0.001 vs. vehicle). Effect of o.g. administration
of control (water; black circles, solid line) or 24mmol/kg L-Arg (white circles, dotted line) on cumulative food intake (H), O2 consumption (I) and CO2
production (J) and respiratory exchange ratio (RER) (K) in mice injected at early light phase and placed in comprehensive laboratory animal monitoring
system cages. The o.g. was performed at 09:00 hours and food was returned at 17:00 hours, as indicated by the dotted line. Recordings were taken over a
period of 24 h and at subsequent 24-min intervals after administration. The shaded areas represent the dark phase from 19:00 hours (n= 12 per group;
*P< 0.05, **P< 0.01, ***P< 0.001 vs. water control). All data are presented as mean± standard error of the mean.
similar magnitude 0–1 h after administration, suggesting that
GPRC6A is not necessary for the anorectic effect of L-Arg
(Figure 2A and B). Oral L-Arg also improved glucose tolerance
in both wt and GPRC6a-KO mice (Figure S2, File S1).
Anorectic Effect of L-Arginine is Not Mediated via the Vagus
Oral gavage of 16mmol/kg L-Arg significantly reduced food
intake in both sham-operated and SDA-operated rats 0–1 h
after administration, suggesting the vagus is not necessary for
the anorectic effect of L-Arg (Figure 2C).
Effect of L-Arginine on Gut Hormone Release
L-Arginine stimulated GLP-1 and PYY release from murine
primary colonic L-cells (Figure 3A andB). Exposure to 100mM
L-Arg for 2 h stimulated PYY release from colonic cultures
isolated from GPRC6a-KO, although the GLP-1 response to
Volume 18 No. 5 May 2016 doi:10.1111/dom.12644 511
original article DIABETES, OBESITY AND METABOLISM
A B C
Figure 2. Effect of L-arginine (L-Arg) on food intake in G-protein-coupled receptor family C group 6 member A (GPRC6a)-KO mice and rats after
subdiaphragmatic vagal deafferentation (SDA) surgery. Effect of oral gavage (o.g.) administration of (A) control (water) or 16mmol/kg L-Arg, and (B)
control (water) or 24mmol/kg L-Arg on 0–1-h food intake in wildtype and GPRC6a-KO mice with ad libitum access to food injected at the beginning of
dark phase [*P< 0.05, **P< 0.01 vs. water control (n= 4, crossover)]. (C) Effect of o.g. of control (water) and 16mmol/kg L-Arg on 0–1-h food intake in
male rats that underwent sham or SDA surgery (n= 9–10, crossover; ***P< 0.001 vs. control). All data are presented as mean± standard error of the mean.
L-Arg appeared to be attenuated in GPRC6a-KO compared
with wt mice (Figure S3, File S1). In keeping with observa-
tions in vitro, oral administration of 16mmol/kg L-Arg elevated
plasma GLP-1 and PYY release in rats. Plasma GLP-1 levels
were significantly elevated at 30 and 90min after administra-
tion compared with control (Figure 3C). PYY levels were sig-
nificantly elevated at 30min after administration (Figure 3D).
Furthermore, direct upper ileal administration of 1M L-Arg
elevated plasma GLP-1 (P< 0.05) and PYY (P= 0.07) levels in
anaesthetized mice and rats (Figure 3E and F).
Effects of L-Arginine-Stimulated Gut Hormone Release
To investigate whether the anorectic effect of L-Arg is medi-
ated by increases in gut hormone levels, GLP-1 andY2 receptors
were simultaneously antagonized inmice receiving 24mmol/kg
L-Arg o.g. The GLP-1 receptor antagonist exendin9-39 and
the Y2 receptor antagonist BIIE0246 were administered i.p. at
doses established to block the anorectic effects of exogenous
exendin-4 and PYY, respectively (Figure S4, File S1). O.g. of
24mmol/kg L-Arg significantly reduced food intake, both in
fasted mice in the early light phase and fed mice in the early
dark phase, whether they were co-administered saline con-
trol or a mixture of 5.26 μmol/kg BIIE0246 and 400 nmol/kg
exendin9-39 (Figure 4A and B).
In line with the hormone release measured in vitro and in
vivo, mucosal Isc measurements showed that L-Arg (1mM)
altered ion transport acutely within 15–30min, while D-Arg
was inactive (Figure 3C–G). Apical treatment of ileal and
colonicmucosae with L-Arg increased Isc initially (potentially a
GLP-1-mediated effect). It then decreased Isc more slowly and,
importantly, this response component was Y1R-dependent and
therefore most likely PYY-mediated (Figure 4C–I).
Effect of Central and Intraperitoneal Administration
of L-Arginine on Food Intake in Rodents
The i.p. administration of 4 and 8mmol/kg L-Arg signifi-
cantly reduced food intake in rats 0–1 h after administration
compared with saline controls (Figure 5A). Similarly, in mice,
12mmol/kg L-Arg significantly reduced food intake 0–1 h after
administration. Food intake was significantly lower in mice
treated with 12mmol/kg L-Arg 4–8 h after administration.The
cumulative food intake at 8 h post-administration was signifi-
cantly lower in both 8 and 12mmol/kg L-Arg groups compared
with the saline control (Figure 5B). Furthermore, i.c.v. admin-
istration of L-Arg significantly reduced food intake in rats at
0–1 h post-administration only, but had no effect on 0–24 h
cumulative food intake (Figure 5C).
Discussion
We investigated the anorectic properties of L-Arg in rodents
and the potential mechanisms by which these effects are medi-
ated. Our data show that L-Arg reduces food intake in both
mice and rats without causing behavioural side effects, but
does not affect energy expenditure in mice at the dose investi-
gated. Repeated L-Arg administration reduced cumulative food
intake on days 1 and 2 in DIO mice, but without significant
effect on body weight over the time studied. The anorectic
effects of L-Arg were not dependent on the amino acid sens-
ing receptorGPRC6Aor on vagal signalling. L-Arg significantly
stimulated GLP-1 and PYY release acutely in vitro and in vivo;
however, its anorectic effects appear unlikely to be mediated by
changes in these gut hormones.
The anorectic effect of L-Arg has been previously shown in
a rat model. Jordi et al. [23] showed a significant reduction in
food intake after o.g. of 6.7mmol/kg L-Arg in rats. In our initial
dose finding studies, doses of 4 and 6mmol/kg of the non-salt
L-Arg solution suppressed food intake in rats; however, equiv-
alent doses of the L-Arg·HCl salt had no effect on food intake
and a dose of 8mmol/kg or higher was required to signifi-
cantly reduce food intake in rats.This suggests that the non-salt
L-Arg may influence food intake at least in part because of its
basicity. To avoid any possible pH-dependent effect, the neu-
tral L-Arg·HCl salt was used in all of our reported experiments.
While it is possible that L-Arg·HCl solution has non-specific
osmotic effects on food intake, pilot studies using isomolar
concentrations of sodium chloride showed no effect of this
concentration of sodium choloride on food intake, and found
that L-Arg reduced food intake compared with iso-osmotic
controls (data not shown).
We found that acute administration of L-Arg had no sig-
nificant effect on VO2 and VCO2 in mice; however, the study
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Figure 3. Effect of L-arginine (L-Arg) on gut hormone release. Effect of L-Arg on (A) glucagon-like peptide-1 (GLP-1) and (B) peptide YY (PYY) release
from primary mice colonic L-cells incubated with 1, 10 and 100mM L-Arg and IBMX-forskolin mix (10 μM, each) for 2 h. The release is shown as
percentages of total hormone contained for each well in the experiment (n= 9 plates from nine mice; *P< 0.05, **P< 0.01, ***P< 0.001 vs. control). Data
presented as mean± standard error of the mean (s.e.m.). Effect of oral gavage (o.g.) administration of control (water) and 16mmol/kg L-Arg on (C) GLP-1,
and (D) PYY in overnight fastedmale rats at 30 and 90min after administration (n= 6–8; *P< 0.05, ***P< 0.001 vs. water control, ##P< 0.01 vs. 12mmol/kg
L-Arg). Data are presented as mean± s.e.m. Effect of intra-ileal administration of saline and 1M L-Arg on plasma GLP-1 and PYY concentrations in
overnight fasted (E) anaesthetized mice and (F) rats. Blood samples were taken from mice at 30min, and from rats at 0, 15, 30, 45 and 60min after
administration (n= 4–5 per group; *P< 0.05 vs. control). Mice results are expressed as mean± s.e.m. Rat results are expressed as area under the curve
(AUC) mean± s.e.m.
showed that o.g. of 24mmol/kg L-Arg significantly reduced
food intake in mice when food was returned 8 h later. This
shows a prolonged anorectic effect that is not necessarily
observable if food is returned immediately. It also suggests
L-Arg can have long-term effects on food intake when food
is not immediately available after administration, which may
be exploitable by weight-loss promoting agents. Furthermore,
RER was significantly lower in the L-Arg-treated cohort once
food was returned.This effect probably reflects the significantly
lower food intake in the L-Arg-treated rodents. Different exper-
imental conditions may alter the pharmacokinetic profile of
L-Arg, and further work is required to determine whether such
long-term effects occur in other contexts. It is also possible that
the effects observed reflect the action of L-Arg metabolites or
other molecules of which it is a precursor, such as nitric oxide
and glutamate; however, simple availability of L-Arg does not
regulate the levels of many of these downstream agents.
Chronic L-Arg supplementation in mice on a low protein
diet has been reported to reduce epididymal fat, while increas-
ing food intake [38]. L-Argmay facilitate increased protein syn-
thesis in animals deficient in protein, but its effects might be
expected to be very different in rodents with a normal protein
intake. We found repeated administration of L-Arg reduced
cumulative food intake but did not significantly influence
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A B C
Figure 5. Effect of intraperitoneal (i.p.) and intracerebroventricular (i.c.v.) administration of L-arginine (L-Arg) on food intake in rodents. Effect of i.p.
administration of (A) control (saline), 4, and 8mmol/kg L-Arg on food intake in fasted male rats (n= 8–9, *P< 0.05, **P< 0.01 vs. control) and (B)
control (saline), 4, 8 and 12mmol/kg L-Arg in fasted male mice (n= 7–9; *P< 0.05, **P< 0.01, ***P< 0.001 vs. control; $$P< 0.01, $$$P< 0.001 vs.
4mmol/kg L-Arg; ##P< 0.01, ###P< 0.001 vs. 8mmol/kg L-Arg) at 0–1, 1–2, 2–4, 4–8 and 0–8 h after administration during early light phase. (C) Effect
of i.c.v. administration of control (saline) and 4 μM L-Arg on food intake in male rats following an overnight fast at 0–1, 1–2, 2–4, 4–8 and 0–24 h after
administration (n= 8–9; *p< 0.05 vs. control). All data are presented as mean± s.e.m.
weight gain in DIO mice. A longer period of administration
and perhaps a higher dose might result in a significant effect
on body weight. Our data do not exclude the possibility of
small changes to body weight that we were unable to detect
in response to chronic L-Arg administration. It is also possible
that L-Arg promotes the absorption of other nutrients or causes
small decreases in energy expenditure that were not detectable
by the CLAMS, which would explain the lack of difference in
body weight. Further work is required to establish the chronic
effects of L-Arg administration on energy homeostasis.
L-Arg can influence hormone release from other endocrine
tissues including the pancreas [17] and the pituitary gland [22].
We therefore investigated the role of anorectic gut hormones
in mediating the effect of L-Arg on food intake. L-Arg stimu-
lated the release of GLP-1 and PYY in vitro and in vivo. Our
data suggested that the anorectic effects of L-Arg are not medi-
ated via gut hormone release, although a potential role for other
gut hormones cannot be excluded. Mucosal studies, however,
complemented the hormonal releasewe observed and indicated
that L-Arg caused acute endogenous PYY release with conse-
quent rapid inhibition of local epithelial ion transport that was
Y1R-mediated. This mechanism is similar to that described for
other amino acids acting via the CaSR in mouse colon [39].
PYY andGLP-1 inhibit gastric emptying, the formermost likely
acting via Y1 and Y2 receptors [40]; PYY(1-36) binds to both
receptors with similar affinity, while the truncated form which
reduces appetite has higher affinity for the Y2 receptor. Further-
more, L-Arg reduces gastric emptying in humans, apparently
via changes in basal levels of nitric oxide [41,42]. In addition,
both GLP-1 and PYY inhibit gastric motility in rats [43,44].
Increased plasma GLP-1 and PYY after L-Arg administration
may slow gastric emptying acutely, but our evidence suggests
that these rapid changes in hormone levels may not be respon-
sible for the subsequent reduction in food intake, which was
not blocked by antagonising either GLP-1 or PYY-Y2 recep-
tors. Both PYY(1-36) and PYY(3-36), however, probably influ-
ence upper gastrointestinal transit, including gastric emptying,
inmice [40], and it is therefore possible that the effects of L-Arg
on PYY(1-36) release alter gastric emptying via the Y1 receptor
sufficiently to account for some of the observed anorectic effect
in mice.
Basic amino acids including L-Arg are potent activators of
GPRC6A [19], which is highly expressed in the gastrointesti-
nal tract and is involved in a number of important physio-
logical pathways [45]. The effects of L-Arg were examined in
mice lacking the GPRC6A at both 24mmol/kg, which was
previously shown to reduce food intake in mice, and at a
lower dose of 16mmol/kg, in case the effects of higher doses
were mediated by different, perhaps non-physiological mech-
anisms; however, at both doses, oral administration of L-Arg
significantly reduced food intake in GPRC6a-KO mice. Previ-
ously, small interfering RNA-induced depletion of endogenous
GPRC6A has been shown to abolish L-ornithine-stimulated
GLP-1 release from GLUTag cells [21]. GPRC6A ablation did
not appear to block L-Arg-induced GLP-1 and PYY release
from a primary cultured murine colonic epithelium, although
the effect on GLP-1 release was attenuated. These data suggest
that GPRC6A is not necessary for the anorectic effects of
L-Arg, and that it plays at most a minor role in its effects on
gut hormone release. L-Arg also activates both T1R1-T1R3
and CaSR receptors, albeit to a lesser extent than GPRC6A
[7]. The involvement of these receptors cannot be ruled out.
L-Arg-induced GLP-1 and PYY release from isolated rat small
intestinal loopswas attenuated by aCaSR antagonist, suggesting
it is in part mediated by CaSR [15].
Other mechanisms may be involved in mediating the effects
of L-Arg. Evidence suggests L-Arg stimulates the release of
insulin from pancreatic 𝛽-cells by causing membrane depo-
larization, and that this effect is not mediated by calcium or
ATP-sensitive potassium channels, but as a consequence of
electrogenic transport of L-Arg into the 𝛽-cell via specific
amino acid transporters [46]. Amino acid transporter systems
may also be involved in amino acid sensing in the gut [14]. In
vitro studies suggest that L-cells exhibit action potential-driven
calcium influx in response to nutrients including amino acids,
leading to acute hormone release. The sodium-coupled neu-
tral amino acid transporter 2 (SNAT2) has been implicated in
nutrient sensing and gut hormone release. SNAT2 acts as a sec-
ondary active transporter by coupling the transfer of amino
acids against their concentration gradient to the simultaneous
inward movement of sodium ions down its electrochemical
gradient. This sodium-dependent transport mechanism has
Volume 18 No. 5 May 2016 doi:10.1111/dom.12644 515
original article DIABETES, OBESITY AND METABOLISM
been shown to increase intracellular calcium levels and conse-
quently to stimulate the release of gut hormones [47]. Notably,
L-glutamine has been shown to stimulate GLP-1 release from
intestinal L-cells via a SNAT2-mediated mechanism [14]. In
addition, the CaSR has been shown to mediate the pharmaco-
logical effects of specific amino acids on gut hormone release
from cell lines and ex-vivo tissue [15,48].
There is evidence that the vagus nerve responds to nutrient
load and is involved in protein-induced satiety [3]. Proteins and
amino acids activate neurons within the nucleus of the solitary
tract via visceral vagusmediated signals. In addition, GLP-1, Y2
and CCK receptors are expressed on vagal afferents which are
proposed to play a key role in gut-brain mediated responses in
satiety and food intake regulation [49]. We examined the effect
of L-Arg on food intake in rats that had undergone SDA surgery
and observed no difference on the effects of L-Arg on food
intake, in accord with previous work suggesting the anorectic
effect of L-Arg is not vagally-mediated [23].
The i.p. or i.c.v. administration of L-Arg significantly reduced
food intake in rats. These findings raise the possibility that
a post-absorptive mechanism may be involved in mediating
the anorectic effects of L-Arg. Jordi et al. [23] suggested that
the anorectic effect of L-Arg is mediated centrally via the area
postrema (AP) in the brain stem. Oral administration of L-Arg
solution increased c-fos positive cells in AP, and the anorectic
effect of L-Argwas abolished in animals that had undergoneAP
lesioning surgery, although, as mentioned earlier, these stud-
ies were performed using the non-salt, basic L-Arg solution.
We have previously reported an increase in c-fos-positive cells
in the AP after oral L-cysteine administration, suggesting that
there may be similar mechanisms by which amino acids influ-
ence food intake [29]. Branched-chain amino acids have also
been shown to reduce food intake in rodents centrally [50].
Recent studies suggest that amember of the soluble carrier fam-
ily of proteins, SLC38A9, may play a role in central L-Arg sens-
ing via mammalian target of rapamycin complex 1-dependent
mechanisms [51]. Further studies are required to investigate the
putative role of post-absorptive mechanisms in the anorectic
effects of L-Arg.
In summary, our data further demonstrate the anorectic
properties of L-Arg and explore the potential mechanisms
involved. The doses of L-Arg administered orally were phar-
macological, with the amounts administered acutely being of
a similar order of magnitude to the levels that a rodent would
consume daily on a 45% high protein diet; however, the present
resultsmay also represent pharmacological activation of a phys-
iological nutrient-sensing system. The present chronic admin-
istration study suggests that L-Argmay not reduce body weight
after repeated dosing, but further work is required to estab-
lish themechanisms involved inmediating the anorectic effects
of L-Arg and to explore whether altering the dose and timing
of chronic administration might result in significant effects on
body weight, and thus suggest therapeutic potential in obesity.
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File S1. L-Arginine promotes gut hormone release and
reduces food intake in rodents.
Table S1. Feeding studies conditions. Table details the exper-
imental conditions including species, phase of the study,
feeding state of the cohort, route of administration and the
dose of L-Arg used for each of the feeding studies described
in the manuscript. The Feeding study (figure) column refers
to the figure number showing the results for each study in the
main manuscript. *All the doses presented in mmol/kg with
exception of the ICV study where the dose is given in μmol.
Figure S1. The effects of oral administration of L-Arg on
behaviour in fasted rats during the light phase. The effect of
OG of water (control) or 16mmol/kg L-Arg in overnight fasted
male rats on feeding, locomotion, grooming, head down, pica
and resting behaviours compared to control group. Data rep-
resented as median (interquartile range) for each observation.
n= 12–13.
Figure S2. The effect of L-Arg on glucose homeostasis in
GPRC6a-KOmice. Glucose tolerance test (GTT) in femaleWT
and GPRC6a-KO mice (A) and the area under the curve for
each treatment (B). Mice were fasted overnight and received an
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intraperitoneal injection of 20% glucose solution (2 g/kg body
weight) followed by an immediate OG of 4mmol/kg L-Arg.
Data is presented as mean± SEM. n= 6 per group. *P< 0.05,
***P< 0.001 WT-L-Arg vs. WT-L-saline; ###P< 0.001 vs.
GPRC6a-KO-L-Arg vs. GPRC6a-WT.
Figure S3. The effect of GPRC6A on GLP-1 and PYY release
from primary murine colonic epithelium. The effect of L-Arg
on GLP-1 (A) and PYY (B) release fromWT and GPRC6A-KO
primary mice colonic L-cells incubated with 100mM L-Arg
for 2 h. The release is shown as percentage of total hormone
contained for each well in the experiment. Data is presented as
mean± SEM. n= 6 plates, from 6 mice. *p< 0.05, ***p< 0.001
vs. control.
Figure S4. The effect of GLP-1 and Y2 receptors antagonism
on the effects of exogenous exendin-4 and PYY on food intake
inmice.The effect of IP administration of 400 nmol/kg exendin
9-39 on the anorectic effect of 1 nmol/kg exogenous exendin-4
in fasted mice at 0–1 h post administration (n= 10) (A). The
effect of IP administration of 5.26 μmol/kg BIIE0246 on the
anorectic effect of 25 nmol/kg PYY(3-36) in fasted mice at
0–1 h post administration (n= 10) (B). Data is presented as
mean± SEM. (A): **P< 0.01 vs. saline control, ###P< 0.001
vs. exendin 9-39, $$P< 0.01 vs. exendin-4; (B): ***P< 0.001
vs vehicle control, ###P< 0.001 vs. BIIE0246, $$P< 0.01 vs.
PYY(3-36).
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